Cargando…

Increased abscopal responses after radiation therapy for oligoprogressive patients receiving immune checkpoint inhibitors?

Detalles Bibliográficos
Autores principales:	Doyen, Jérôme, Levy, Antonin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174830/ https://www.ncbi.nlm.nih.gov/pubmed/37180659 http://dx.doi.org/10.21037/tcr-23-37

Ejemplares similares

Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy
por: Sindhu, Kunal K., et al.
Publicado: (2022)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers
por: Voutsadakis, Ioannis A
Publicado: (2018)

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
por: Liu, Yang, et al.
Publicado: (2018)

The Abscopal Effect in the Era of Checkpoint Inhibitors
por: Kodet, Ondřej, et al.
Publicado: (2021)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Is there a role for stereotactic body radiation before immune checkpoint inhibitor therapy for advanced hepatocellular carcinoma?
por: Mukherjee, Sandeep
Publicado: (2023)

Successful Treatment of Advanced Gastric Cancer with Brain Metastases through an Abscopal Effect by Radiation and Immune Checkpoint Inhibitor Therapy
por: Muto, Momotaro, et al.
Publicado: (2021)

Editorial Comment to Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors
por: Yuasa, Takeshi
Publicado: (2019)

Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer
por: Oei, Arlene L., et al.
Publicado: (2019)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
por: Schoenhals, Jonathan E., et al.
Publicado: (2021)

The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
por: Buchwald, Zachary S., et al.
Publicado: (2018)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors
por: Ishiyama, Yudai, et al.
Publicado: (2019)

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Immune checkpoint inhibitor in liver cancer—unique regional differences
por: Obi, Shuntaro, et al.
Publicado: (2020)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

mRNA-based COVID-19 vaccines appear not to increase immune events in cancer patients receiving immune checkpoint inhibitors
por: Yekedüz, Emre, et al.
Publicado: (2021)

Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice
por: Lerrer, Shalom, et al.
Publicado: (2019)

Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
Publicado: (2022)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy
por: Jackson, Christopher B., et al.
Publicado: (2022)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
por: Reshko, Leonid B., et al.
Publicado: (2021)

Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases
por: Berber, Tanju, et al.
Publicado: (2022)

Challenges of predicting immune checkpoint therapy responders in lung cancer
por: Marwitz, Sebastian
Publicado: (2019)

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
por: Menon, Hari, et al.
Publicado: (2019)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Systemic benefit of radiation therapy via abscopal effect
por: Craig, Daniel J., et al.
Publicado: (2022)

Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors
por: Arasanz, Hugo, et al.
Publicado: (2023)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
por: Longo, Vito, et al.
Publicado: (2019)

The abscopal effect in patients with cancer receiving immunotherapy
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses
por: Zeng, Jing, et al.
Publicado: (2013)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
por: Guida, Michele, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dmvbnl9dr63sukf16g5tes3rf7